Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 13 | 2026 | 218 | 2.270 |
Why?
|
| Living Donors | 6 | 2024 | 79 | 1.230 |
Why?
|
| Hepatectomy | 4 | 2024 | 63 | 1.120 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2024 | 176 | 1.110 |
Why?
|
| Liver Neoplasms | 5 | 2024 | 309 | 1.040 |
Why?
|
| Patient Selection | 3 | 2015 | 483 | 0.440 |
Why?
|
| Tissue Donors | 3 | 2018 | 146 | 0.440 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 369 | 0.420 |
Why?
|
| Donor Selection | 1 | 2012 | 15 | 0.360 |
Why?
|
| Laparoscopy | 1 | 2013 | 492 | 0.290 |
Why?
|
| Bile Duct Neoplasms | 1 | 2008 | 59 | 0.280 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 326 | 0.270 |
Why?
|
| Hepatitis C | 2 | 2024 | 145 | 0.250 |
Why?
|
| Organ Preservation | 1 | 2026 | 22 | 0.240 |
Why?
|
| Antiviral Agents | 3 | 2024 | 323 | 0.240 |
Why?
|
| Perfusion | 1 | 2026 | 74 | 0.240 |
Why?
|
| Hypothermia, Induced | 1 | 2026 | 40 | 0.240 |
Why?
|
| Reperfusion Injury | 1 | 2026 | 57 | 0.240 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2024 | 30 | 0.220 |
Why?
|
| Learning Curve | 1 | 2024 | 33 | 0.220 |
Why?
|
| Waiting Lists | 2 | 2018 | 56 | 0.200 |
Why?
|
| Pancreas Transplantation | 1 | 2002 | 19 | 0.190 |
Why?
|
| Celiac Disease | 1 | 2002 | 19 | 0.190 |
Why?
|
| Postoperative Complications | 2 | 2024 | 1311 | 0.180 |
Why?
|
| Drainage | 1 | 2002 | 153 | 0.180 |
Why?
|
| Robotic Surgical Procedures | 1 | 2024 | 170 | 0.170 |
Why?
|
| Hepatitis C, Chronic | 1 | 2021 | 89 | 0.160 |
Why?
|
| Liver | 3 | 2011 | 867 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 406 | 0.150 |
Why?
|
| Portal Vein | 2 | 2026 | 39 | 0.150 |
Why?
|
| Transplantation, Homologous | 4 | 2011 | 249 | 0.140 |
Why?
|
| Blood Group Incompatibility | 1 | 2018 | 10 | 0.140 |
Why?
|
| Resource Allocation | 1 | 2018 | 20 | 0.140 |
Why?
|
| Health Plan Implementation | 1 | 2018 | 40 | 0.140 |
Why?
|
| Prognosis | 4 | 2024 | 1773 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2002 | 629 | 0.130 |
Why?
|
| Graft Survival | 2 | 2026 | 297 | 0.130 |
Why?
|
| Humans | 16 | 2026 | 64778 | 0.120 |
Why?
|
| Minority Groups | 1 | 2018 | 141 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2024 | 5764 | 0.120 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2015 | 10 | 0.110 |
Why?
|
| Female | 11 | 2026 | 33765 | 0.100 |
Why?
|
| Middle Aged | 10 | 2026 | 18112 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2024 | 6811 | 0.100 |
Why?
|
| Male | 10 | 2026 | 30812 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2015 | 154 | 0.100 |
Why?
|
| Survival Rate | 3 | 2024 | 847 | 0.090 |
Why?
|
| Liver Circulation | 1 | 2011 | 11 | 0.090 |
Why?
|
| Iohexol | 1 | 2011 | 18 | 0.090 |
Why?
|
| Poloxamer | 1 | 2011 | 16 | 0.090 |
Why?
|
| Hepatic Veins | 1 | 2011 | 13 | 0.090 |
Why?
|
| Hepatic Artery | 1 | 2011 | 22 | 0.090 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 64 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 640 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2483 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2011 | 240 | 0.070 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2008 | 1 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 2011 | 331 | 0.070 |
Why?
|
| Ganciclovir | 1 | 2008 | 18 | 0.070 |
Why?
|
| Iron Overload | 1 | 2007 | 5 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 371 | 0.070 |
Why?
|
| Liver Failure | 1 | 2007 | 18 | 0.070 |
Why?
|
| Viral Matrix Proteins | 1 | 2008 | 50 | 0.070 |
Why?
|
| Anastomosis, Surgical | 2 | 2011 | 119 | 0.070 |
Why?
|
| Global Health | 1 | 2008 | 180 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 68 | 0.070 |
Why?
|
| Adult | 6 | 2026 | 17243 | 0.070 |
Why?
|
| Cytomegalovirus | 1 | 2008 | 94 | 0.060 |
Why?
|
| Bacteremia | 1 | 2007 | 92 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2008 | 223 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 135 | 0.060 |
Why?
|
| Reoperation | 1 | 2006 | 299 | 0.060 |
Why?
|
| Incidence | 1 | 2008 | 1410 | 0.050 |
Why?
|
| Operative Time | 1 | 2024 | 91 | 0.050 |
Why?
|
| Tissue and Organ Procurement | 2 | 2018 | 39 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2024 | 134 | 0.050 |
Why?
|
| Aged | 5 | 2024 | 14840 | 0.050 |
Why?
|
| Sustained Virologic Response | 1 | 2021 | 9 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2021 | 13 | 0.040 |
Why?
|
| Fluorenes | 1 | 2021 | 13 | 0.040 |
Why?
|
| Sofosbuvir | 1 | 2021 | 16 | 0.040 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2021 | 20 | 0.040 |
Why?
|
| Time Factors | 4 | 2011 | 3753 | 0.040 |
Why?
|
| Carbamates | 1 | 2021 | 26 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2021 | 37 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2021 | 166 | 0.040 |
Why?
|
| Benzimidazoles | 1 | 2021 | 56 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 295 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2021 | 136 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2018 | 31 | 0.030 |
Why?
|
| Isoantibodies | 1 | 2018 | 35 | 0.030 |
Why?
|
| Recurrence | 2 | 2009 | 655 | 0.030 |
Why?
|
| United States | 2 | 2024 | 8051 | 0.030 |
Why?
|
| Phlebography | 1 | 2011 | 45 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2011 | 138 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 241 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 395 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 579 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 414 | 0.020 |
Why?
|
| Risk Factors | 2 | 2009 | 5399 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 539 | 0.020 |
Why?
|
| Transplants | 1 | 2007 | 8 | 0.020 |
Why?
|
| Viremia | 1 | 2008 | 45 | 0.020 |
Why?
|
| Viral Load | 1 | 2008 | 228 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 231 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2007 | 201 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 734 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1382 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 2091 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 1556 | 0.010 |
Why?
|
| Veterans | 1 | 2007 | 755 | 0.010 |
Why?
|
| Animals | 1 | 2011 | 21310 | 0.010 |
Why?
|